Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from
Jean-Christophe Stauffer1, Jean-Jacques Goy, Nicole Duvoisin
1Service de cardiologie, Hôpital Cantonal, Fribourg, Switzerland. jean-christophe.stauffer@chuv.ch
Insights
Early administration of clopidogrel with aspirin significantly reduces mortality and major adverse cardiac events in acute coronary syndrome patients. Combining early clopidogrel with primary PCI offers the greatest benefit.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes (ACS) carry a high risk of vascular events.
- Early intervention is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of early clopidogrel administration (300 mg, <24 hours) combined with aspirin in ACS patients.
- To assess the impact on mortality and major adverse cardiac events (MACE).
Main Methods:
- A cohort of 30,243 ACS patients was analyzed.
- Early clopidogrel administration data was available for 24,463 patients.
- 51% received clopidogrel within 24 hours of admission.
Main Results:
- In-hospital death was 2.9% in the early clopidogrel + primary PCI group vs. 11.4% in the no-early-clopidogrel group.
- MACE incidence was 4.1% in the early clopidogrel + primary PCI group vs. 13.5% in the other group.
- Multivariate analysis identified early clopidogrel and PCI as key factors reducing mortality.
Conclusions:
- Early clopidogrel administration with aspirin benefits ACS patients, reducing mortality and MACE.
- The combination of primary PCI and early clopidogrel administration is particularly effective.
Background:
Patients who have acute coronary syndromes with or without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy of early clopidogrel administration (300 mg) (<24 hours) when given with aspirin in such patients.
Methods:
We included 30,243 patients who had an acute coronary syndrome with or without ST segment elevation. Data on early clopidogrel administration were available for 24,463 (81%). Some 15,525 (51%) of the total cohort were administrated clopidogrel within 24h of admission.
Results:
In-hospital death occurred in 2.9% of the patients in the early clopidogrel group treated with primary PCI and in 11.4% of the patients in the other group without primary percutaneous coronary intervention (PCI) and no early clopidogrel. The unadjusted clopidogrel odds ratio (OR) for mortality was 0.31 (95% confidence interval 0.27-0.34; p <0.001). Incidence of major adverse cardiac death (MACE) was 4.1% in the early clopidogrel group treated with 1°PCI and 13.5% in the other group without primary PCI and no early clopidogrel (OR 0.35, confidence interval 0.32-0.39, p <0.001). Early clopidogrel administration and PCI were the only treatment lowering mortality as shown by mutlivariate analysis.
Conclusions:
The early administration of the anti-platelet agent clopidogrel in patients with acute coronary syndromes with or without ST-segment elevation has a beneficial effect on mortality and major adverse cardiac events. The lower mortality rate and incidence of MACE emerged with a combination of primary PCI and early clopidogrel administration.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:27Coronary Artery Disease V: Interprofessional Care